TT-4: 一种A2bR拮抗剂药物，由Tarus Therapeutics, Inc. (Tarus Therapeutics, Inc.)公司最早进行研发，目前全球最高研发状态为临床1期，作用机制: A2bR拮抗剂 (腺苷A2b受体拮抗剂)，治疗领域: 肿瘤,消化系统疾病，在研适应症: 实体瘤,结直肠癌，在研机构: Portage Biotech, Inc.,Impetis ...

TT语音PC版 轻快纯净低占用, 音质清晰无延迟

2023年11月2日 · BACKGROUND: In the context of the TT4 study, a phase 3 trial was conducted to investigate whether a modified fixed duration treatment approach, known as L-TT4, could …

• 119 audiovisual lectures that teach every core concept in the standard 4th grade curriculum. • thousands of problems that give students all the practice they need to master each concept. • automated grading and instant feedback for every single problem.

背景TT-10 和TT-4 分别是腺苷A2A 受体 (A2AR) 和A2B 受体 (A2BR) 的强效和选择性拮抗剂。 这两种药物都被开发用于治疗晚期癌症，最初是作为单一疗法，使用肿瘤组织中高水平的腺苷受体表达作为生物标志物。

Teaching Textbooks is a complete math curriculum offered as a series of apps (one for each grade level). Each course does all of the teaching, all of the grading, and has step-by-step solutions for every problem. These features allow students to work independently and take the weight of teaching math off the parents!

2021年7月6日 · 多中心、开放标签剂量递增 I/II 期临床研究，旨在评估 TT-4 在诊断为结直肠癌 (CRC)、胃癌的受试者中的安全性、耐受性、PK、PD、抗肿瘤活性和疗效 (GC)、肝细胞癌 (HCC) 和局部晚期、不可切除或转移性胰腺癌 (PANC)；未能或不符合标准护理治疗条件的人。

2024年7月15日 · The Teaching Textbooks Math 4 app makes your TT course even better! Not only will your student enjoy math while learning independently, but, with the app, that learning can also take...

2021年4月28日 · Tarus Therapeutics Inc., a clinical-stage biotechnology company developing adenosine receptor antagonists for cancer immunotherapy, today announced that it submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) on April 26, 2021 to support the initiation of a clinical study of TT-4, an oral small ...

This app provides access to ALL your Teaching Textbooks (TT) Math 4 course materials on a Windows device! Enrollment in the TT Math 4 course is required. The Teaching Textbooks Math 4 app makes your TT course even better!